Head-to-head · free

U.S. Physical Therapy vs Xenon Pharmaceuticals Inc.

USPH vs XENE — return on capital, cash generation, margins and balance sheet side by side.

USPH

3 / 4

measures where USPH leads

XENE

1 / 4

measures where XENE leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureUSPH · FY2025XENE · FY2025
Revenue$781.0M—
Net income$39.6M(345.9M)
Revenue growth (yearly, multi-year)12.1%—
Free cash flow—(279.9M)
Free cash flow margin——
Net cash / (debt)——
ROIC6.0%—
Return on equity3.1%-51.8%
Gross margin19.2%—
Operating margin10.3%-4974.3%
Net debt / EBITDA1.16x0.54x

Figures are as reported by each company; latest fiscal year shown.

Where U.S. Physical Therapy's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full USPH profile →

Where Xenon Pharmaceuticals Inc.'s cash went (FY2025)

Capital spending
$799000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full XENE profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons